Lelisa F. Gemta

Lelisa F. Gemta

Auto-generated profile, based on publicly available information

Lelisa F. Gemta

Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2019 in Science Immunology
Verified
Journal Article
Closed access
PDF file
LGLelisa F. Gemta
Lelisa F. Gemta
PSPeter J. Siska
Peter J. Siska
MNMarin E. Nelson
Marin E. Nelson
XGXia Gao
Xia Gao
XLXiaojing Liu
Xiaojing Liu
TBTimothy N Bullock
Timothy N Bullock
Impaired activity of enolase 1 limits glycolysis and effector function of tumor-infiltrating CD8 + T cells.

27 October 2020 in Science Signaling
Verified
Journal Article
Closed access
PDF file
SSScott M. Seki
Scott M. Seki
KPKacper Posyniak
Kacper Posyniak
RMRebecca McCloud
Rebecca McCloud
DRDorian A. Rosen
Dorian A. Rosen
AFAnthony Fernández-Castañeda
Anthony Fernández-Castañeda
AGAlban Gaultier
Alban Gaultier
Small molecules that promote the metabolic activity of the pyruvate kinase isoform PKM2, such as TEPP-46 and DASA-58, limit tumorigenesis and inflammation. To understand how these compounds alter T cell function, we assessed their therapeutic activity in a mouse model of T cell–mediated autoimmunity that mimics multiple sclerosis (MS). TH17 cells are believed to orchestrate MS pathology, in part, through the production of two proinflammatory cytokines: interleukin-17 (IL-17) and GM-CSF. We found that both TEPP-46 and DASA-58 suppressed the development of IL-17–producing TH17 cells but increased the generation of those producing GM-CSF. This switch redirected disease pathology from the spinal cord to the brain. In addition, we found that activation of PKM2 interfered with TGF-β1 signaling, which is necessary for the development of TH17 and regulatory T cells. Collectively, our data clarify the therapeutic potential of PKM2 activators in MS-like disease and how these agents alter T cell function.